Pathogenesis and prevention of dengue virus infection: State-of-the-art

Current Opinion in Infectious Diseases

Volumn 22, Issue 3, 2009, Pages 302-308

  Tan, Grace K ^a   Alonso, Sylvie ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Centre for Life Sciences   (Singapore)

Author keywords

Antibody enhancement; Dengue fever; Dengue hemorrhagic fever; Dengue shock syndrome; Dengue vaccine

Indexed keywords

CD209 ANTIGEN; CHIMERIVAX; COMPLEMENT COMPONENT C1Q; CYTOKINE; DENGUE VACCINE; FC RECEPTOR; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MANNOSE RECEPTOR; NONSTRUCTURAL PROTEIN 1; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AEDES AEGYPTI; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT ENHANCEMENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CLINICAL TRIAL; DENDRITIC CELL; DENGUE; DENGUE VIRUS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; DOWN REGULATION; DRUG SAFETY; DRUG TOLERABILITY; HEREDITY; HLA SYSTEM; HOST RESISTANCE; HOST SUSCEPTIBILITY; HUMAN; IMMUNE SYSTEM; LACTOCOCCUS LACTIS; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOGENESIS; REVIEW; T LYMPHOCYTE; TARGET CELL; VACCINE PRODUCTION; VECTOR CONTROL; VIRUS REPLICATION; VIRUS VIRULENCE; IMMUNOLOGY; METHODOLOGY; MOSQUITO; PATHOLOGY;

DENGUE; DENGUE VACCINES; HUMANS; MOSQUITO CONTROL;

EID: 65549166750     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328329ae32     Document Type: Review

References (74)

1. Benedict MQ, Levine RS, Hawley WA, et al. Spread of the tiger: global risk of invasion by the mosquito Aedes albopictus. Vector Borne Zoonotic Dis 2007; 7:76-85.
2. Halstead SB. Dengue. Lancet 2007; 370:1644-1652; review.
3. 'Guidelines for the clinical evaluation of dengue vaccines in endemic areas': summary of a World Health Organization Technical Consultation. Vaccine 2008; 26:4113-4119.
4. Gulati S, Maheshwari A. Atypical manifestations of dengue. Trop Med Int Health 2007; 12:1087-1095. A review summarizing the various atypical manifestations of DEN, including DEN-associated encephalitis, myocarditis, hepatitis and cholecystitis.
5. Wasay M, Channa R, Jumani M, et al. Encephalitis and myelitis associated with dengue viral infection. Clinical and neuroimaging features. Clin Neurol Neurosurg 2008; 110:635-640.
6. Park SB, Ryu SY, Jin EA, et al. Acute colitis associated with dengue fever in a renal transplant recipient. Transplant Proc 2008; 40:2431-2432.
7. Teixera MG, Costa MC, Coehlo G, Barreto ML. Recent shift in age pattern of dengue hemorrhagic fever, Brazil. Emerg Infect Dis 2008; 14:1663-1665.
8. Ooi EE, Goh KY, Gubler DJ. Dengue prevention and 35 years of vector control in Singapore. Emerg Infect Dis 2006; 12:887-893.
9. Hammond SN, Balmaseda A, Perez L, et al. Differences in dengue severity in infants, children and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg 2005; 73:1063-1070.
10. Wu SJ, Grouard-Vogel G, Sun W, et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000; 6:816-820.
11. Navarro-Sanchez E, Altmeyer R, Amara A, et al. Dendritic-cell-specific ICAM3-grabbing nonintegrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO J 2003; 4:723-728.
12. Miller JL, de Wet BJ, Martinez-Pomares L, et al. The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog 2008; 4:e17. A novel functional role for mannose receptor in DEN infection; it is shown in this study to bind to the envelope glycoproteins of all four DEN virus serotypes.
13. van der Schaar HM, Rust MJ, Waarts BL, et al. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. J Virol 2007; 81:12019-12028.
14. Krishnan MN, Sukumaran B, Pal U. Rab 5 is required for the cellular entry of dengue and West Nile viruses. J Virol 2007; 81:4881-4885.
15. Kwan W, Navarro-Sanchez E, Dumortier H, et al. Dermal-type macrophages expressing CD209/DC-SIGN show inherent resistance to dengue virus growth. PLoS Neglected Trop Dis 2008; 2:e311. This study presents a novel means to curb DEN spread at the initial site of infection by viral sequestration in early phagosomes of dermal-type macrophages.
16. Clyde K, Kyle JL, Harris E. Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol 2006; 80:11418-11431.
17. Warke RV, Becerra A, Zawadzka A, et al. Efficient dengue virus (DENV) infection of human muscle satellite cells upregulates type I interferon response genes and differentially modulates MHC I expression on bystander and DENV-infected cells. J Gen Virol 2008; 89:1605-1615.
18. Palmer DRP, Sun P, Celluzzi C, et al. Differential effects of dengue virus on infected and bystander dendritic cells. J Virol 2005; 2432-2439.
19. Yen Y-T, Chen H-C, Lin Y-D, et al. Enhancement by tumor necrosis factor alpha of dengue virus-induced endothelial cell production of reactive nitrogen and oxygen species is key to hemorrhage development. J Virol 2008; 82: 12312-12324.
20. Nasirudeen AMA, Wang L, Liu DX. Induction of p53-dependent and mitochondria-mediated cell death pathway by dengue virus infection of human and animal cells. Microb Infect 2008; 10:1124-1132.
21. Boonnak K, Slike BM, Burgess TH, et al. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol 2008; 82:3939-3951.
22. Chareonsirisuthigul T, Kalayanarooj S, Ubol S. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of antiinflammatory cytokines, but suppresses anti-DENV free radical and proinflammatory cytokine production, in THP-1 cells. J Gen Virol 2007; 88: 365-375. The authors introduced the concept of intracellular ADE in DEN infection; ADE infection not only facilitated the entry process, but also significantly modified the innate and adaptive intracellular antiviral mechanisms, translating into enhanced cellular infectivity.
23. Brown MG, King CA, Sherren C, et al. A dominant role for FcgammaRII in antibody-enhanced dengue virus infection of human mast cells and associated CCL5 release. J Leukoc Biol 2006; 80:1242-1250.
24. Brown MG, Huang YY, Marshall JS. Dramatic caspase-dependent apoptosis in antibody-enhanced dengue virus infection of human mast cells. J Leukoc Biol 2009; 85:71-80. The first study investigating the effect of ADE on DEN virus-induced apoptosis.
25. Mongkolsapaya J, Dkuaangchinda T, Dejnirattisai W, et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal? J Immunol 2006; 176:3821-3829.
26. Dejnirattisai W, Duangchinda T, Lin CL, et al. A complex interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections. J Immunol 2008; 181:5865-5874. This study has integrated several players (endothelial cells, dendritic cells, T cells and cytokines) involved in DEN pathogenesis to reconstitute a possible in-vivo scenario.
27. Imrie A, Meeks J, Gurary A. Differential functional avidity of dengue virusspecific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol 2007; 81:10081-10091.
28. Mangada MM, Rothman AL. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol 2005; 175:2676-2683.
29. Chaturvedi UC, Agarwal R, Elbishbishi EA, et al. Cytokine cascade in dengue haemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol 2000; 28:183-188.
30. Chaturvedi UC, Shrivastava R, Tripathi RK, et al. Dengue virus-specific suppressor T cells: current perspectives. FEMS Immunol Med Microbiol 2007; 50:285-299.
31. Basu A, Chaturvedi UC. Vascular endothelium: the battlefield of dengue viruses. FEMS Immunol Med Microbiol 2008; 53:287-299. A comprehensive review of the factors that contribute to altered vascular endothelial cell physiology and damage, proposed to be responsible for DHF/DSS.
32. Lin CF, Wan SW, Cheng HJ, et al. Autoimmune pathogenesis in dengue virus infection. Viral Immunol 2006; 19:127-132.
33. Lin CF, Wan SW, Chen MC, et al. Liver injury caused by antibodies against dengue virus nonstructural protein 1 in a murine model. Lab Invest 2008; 88:1079-1089.
34. Cheng HJ, Lin CF, Lei HY, et al. Proteomic analysis of endothelial cell autoantigens recognized by anti-dengue virus nonstructural protein 1 antibodies. Exp Biol Med (Maywood) 2009; 234:63-73. This study employed high-throughput proteomic analysis for the identification of putative targets on endothelial cells recognized by NS1 antibodies and determined the shared epitopes on NS1.
35. Avirutnan P, Punyadee N, Noisakran S, et al. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis 2006; 193:1078-1088.
36. Kurosu T, Chaichana P, Yamate M, et al. Secreted complement regulatory protein clusterin interacts with dengue virus nonstructural protein 1. Biochem Biophys Res Commun 2007; 362:1051-1056.
37. Chaturvedi UC, Nagar R, Shrivastava R. Dengue and dengue hemorrhagic fever: implications of host genetics. FEMS Immunol Med Microbiol 2006; 47:155-166.
38. Lan NT, Kikuchi M, Huong VT, et al. Protective and enhancing HLA alleles, HLA-DRB1 *0901 and HLA-A*24, for severe forms of dengue virus infection, dengue hemorrhagic fever and dengue shock syndrome. PLoS Negl Trop Dis 2008; 2:e304.
39. Fernández-Mestre MT, Gendzekhadze K, Rivas-Vetencourt P, et al. TNF-alpha-308A allele, a possible severity risk factor of hemorrhagic manifestation in dengue fever patients. Tissue Antigens 2004; 64:469-472.
40. Chao YC, Huang CS, Lee CN, et al. Higher infection of dengue virus serotype 2 in human monocytes of patients with G6PD deficiency. PLoS ONE 2008; 3:e1557.
41. Mehlhop E, Ansarah-Sobrinho C, Johnson S, et al. Complement protein C1 q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microb 2007; 2:417-426. The first description of a mechanism involved in the restriction of ADE.
42. Chang PE, Cheng CL, Asok K, et al. Visual disturbances in dengue fever: an answer at last? Singapore Med J 2007; 48:e71-e73.
43. Acioli-Santos B, Segat L, Dhalia R, et al. MBL2 gene polymorphisms protect against development of thrombocytopenia associated with severe dengue phenotype. Hum Immunol 2008; 69:122-128.
44. Pandey BD, Morita K, Hasebe F, et al. Molecular evolution, distribution and genetic relationship among the dengue 2 viruses isolated from different clinical severity. Southeast Asian J Trop Med Public Health 2000; 31:266-272.
45. Leitmeyer KC, Vaughn DW, Watts DM, et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 1999; 73:4738-4747.
46. Rico-Hesse R, Harrison LM, Salas RA, et al. Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology 1997; 230:244-251.
47. Prestwood TR, Prigozhin DM, Shara KL, et al. A mouse-passaged dengue virus strain with reduced affinity for heparin sulphate causes severe disease in mice by establishing increased systemic viral loads. J Virol 2008; 82:8411-8421.
48. Yauch LE, Sheresta S. Mouse models of dengue virus infection and disease. Antiviral Res 2008; 80:87-93. This review is a compilation of the various mouse models in use today as well as those currently in development for the study of DEN pathogenesis.
49. Ra S, Santos ND, Silva CS, et al. Larvicidal activity of lectins from Myracrodruon unrundeuva on Aedes aegypti. Comp Biochem Physiol C Toxicol Pharmacol 2008 [Epub ahead of print].
50. Billingsley PF, Foy B, Rasgon JL. Mosquitocidal vaccines: a neglected addition to malaria and dengue control strategies. Trends Parasitol 2008; 24:396-400. The above article gives an overview and critical comments on mosquitocidal vaccines as an alternative approach for vector control.
51. Speranca MA, Capurro ML. Perspectives in the control of infectious diseases by transgenic mosquitoes in the postgenomic era: a review. Mem Inst Oswaldo Cruz, Rio de Janeiro 2007; 102:425-433.
52. Roehrig JT, Hombach J, Barrett AD. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 2008; 21:123-132.
53. Sabchareon A, Lang J, Chantavanich P, et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio and multiple dose. Am J Trop Med Hyg 2002; 66:264-272.
54. Sun W, Edelman R, Kanesa-thasan N, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003; 69:24-31.
55. Hermida L, Bernardo L, Martin J, et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 2006; 24:3165-3171.
56. Raviprakash K, Wang D, Ewing D, et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in Rhesus monkeys against all four serotypes of dengue virus. J Virol 2008; 82:6927-6934. This study brings the evidence that a nonuniform antibody response generated upon vaccination with a tetravalent formulation does not necessarily translate into different levels of protection against the four serotypes; it suggests that each serotype may have different protection thresholds.
57. Bernardo L, Hermida L, Martin J, et al. Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch Virol 2008; 153:849-854. The above article provides evidence that the antibody responses generated upon viral challenge of immunized animals may represent a better correlate of protection than the antibody titres generated upon vaccination.
58. Guy B, Almond JW. Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis 2008; 31:239-252. The above article reviews the various DEN vaccine candidates and their different development stages. Also discusses data and information obtained from preclinical and clinical studies. 59 Whitehead SS, Blaney JE, Durbin AP, et al. Prospects for a dengue virus vaccine. Nature Rev Microbiol 2007; 5:518-528.
59. Wilder-Smith A, Deen JL. Dengue vaccines for travelers. Expert Rev Vaccines 2008; 7:569-578.
60. Edelman R, Wassermann SS, Bodison SA, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69:48-60.
61. Simasathien S, Thomas SJ, Watanaveeradej V, et al. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naïve children. Am J Trop Med Hyg 2008; 78:426-433.
62. Sun W, Cunningham D, Wasserman SS, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum Vaccines 2008; 5:1-8.
63. Guirakhoo F, Kitchener S, Morrison D, et al. Live-attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever preimmunity in induction of cross-neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccines 2006; 2:60-67.
64. Guy B, Nougarede N, Begue S, et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naïve or flavivirus-primed subjects. Vaccine 2008; 26:5712-5721.
65. McGee CE, Lewis MG, St. Claire M, et al. Recombinant chimeric virus with wild-type dengue 4 virus premembrane and envelope and virulent yellow fever virus Asibi backbone sequences is dramatically attenuated in nonhuman primates. J Infect Dis 2008; 197:693-697.
66. Durbin AP, Whitehead SS, McArthur J, et al. rDEN4Δ30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic and highly infectious in healthy adult volunteers. J Infect Dis 2005; 191:710-718.
67. Durbin AP, McArthur J, Marron JA, et al. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccines 2006; 2:167-173.
68. Durbin AP, McArthur J, Marron JA, et al. rDEN2/4Δ30 (ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccines 2006; 5:255-260.
69. Blaney JE, Sathe NS, Goddard L, et al. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-33′-UTR with that of DENV-4. Vaccine 2008; 26:817-828.
70. McArthur JH, Durbin AP, Marron JA, et al. Phase I clinical evaluation of rDEN4delta30-200, 201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg 2008; 79:678-684.
71. Etemad B, Batra G, Raut R, et al. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg 2008; 79:353-363.
72. Gao G, Wang Q, Dai Z, et al. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes. Hum Vaccines 2008; 19:927-936.
73. Brandler S, Lucas-Hourani M, Moris A, et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLOS one 2008; 1:e96. In this study, a pediatric measles vaccine coexpressing DENV1 EDIII and the 40-residue intraluminal ectodomain of M protein (ectoM) was reported to trigger in mice a long-term production of DENV1 serotype-specific neutralizing antibody response together with a strong anti-MV antibody response.
74. Sim A, Lin W, Tan GK, et al. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen. Vaccine 2008; 26:1145-1154.